HER-2 and NF-κB as the targets for therapy-resistant breast cancer

Kazi M. Ahmed, Ning Cao, Jian-Jian Li

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

HER-2 (also called ErbB2 or Neu) tyrosine kinase, one of the four members of ErbB receptor family (ErbB1, i.e., EGFR, ErbB2, ErbB3 and ErbB4), plays a critical role in the control of diverse cellular functions involved in differentiation, proliferation, migration and cell survival via multiple signal transduction pathways. Overexpression of HER-2, observed in HER-2-positive breast cancer patients, is believed to cause the tumor resistance to an array of anti-cancer agents and poor prognosis. Although HER-2 antibodies have shown growth inhibitory effects, more efficient molecular targets against HER-2-mediated tumor resistance need to be developed. The molecular mechanisms underlying HER-2-mediated tumor resistance, especially the connections between HER-2 and therapy-resistant signaling networks, need to be further investigated. NF-KB, a key stress transcription factor that can initiate a pro-survival network, was found to be activated in many cancer cells overexpressing HER-2 and to be responsible for the radiation resistance in HER-2 transfected breast cancer cells. Recent findings in literature and data from this laboratory suggest a possible co-operation between HER-2 and NF-κB in signaling tumor resistance to radiotherapy. This review will discuss the mechanisms of HER-2 mediated NF-κB signaling pathway and potential target for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)4235-4243
Number of pages9
JournalAnticancer Research
Volume26
Issue number6 B
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Therapeutics
Protein-Tyrosine Kinases
Signal Transduction
Cell Survival
Transcription Factors
Radiotherapy
Radiation
Survival
Antibodies
Growth

Keywords

  • Drug resistance
  • HER-2
  • Herceptin
  • NF-κB
  • Radiotherapy resistance
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2 and NF-κB as the targets for therapy-resistant breast cancer. / Ahmed, Kazi M.; Cao, Ning; Li, Jian-Jian.

In: Anticancer Research, Vol. 26, No. 6 B, 11.2006, p. 4235-4243.

Research output: Contribution to journalArticle

Ahmed, Kazi M. ; Cao, Ning ; Li, Jian-Jian. / HER-2 and NF-κB as the targets for therapy-resistant breast cancer. In: Anticancer Research. 2006 ; Vol. 26, No. 6 B. pp. 4235-4243.
@article{376119f31c554d0683ea45b842724c6d,
title = "HER-2 and NF-κB as the targets for therapy-resistant breast cancer",
abstract = "HER-2 (also called ErbB2 or Neu) tyrosine kinase, one of the four members of ErbB receptor family (ErbB1, i.e., EGFR, ErbB2, ErbB3 and ErbB4), plays a critical role in the control of diverse cellular functions involved in differentiation, proliferation, migration and cell survival via multiple signal transduction pathways. Overexpression of HER-2, observed in HER-2-positive breast cancer patients, is believed to cause the tumor resistance to an array of anti-cancer agents and poor prognosis. Although HER-2 antibodies have shown growth inhibitory effects, more efficient molecular targets against HER-2-mediated tumor resistance need to be developed. The molecular mechanisms underlying HER-2-mediated tumor resistance, especially the connections between HER-2 and therapy-resistant signaling networks, need to be further investigated. NF-KB, a key stress transcription factor that can initiate a pro-survival network, was found to be activated in many cancer cells overexpressing HER-2 and to be responsible for the radiation resistance in HER-2 transfected breast cancer cells. Recent findings in literature and data from this laboratory suggest a possible co-operation between HER-2 and NF-κB in signaling tumor resistance to radiotherapy. This review will discuss the mechanisms of HER-2 mediated NF-κB signaling pathway and potential target for therapeutic intervention.",
keywords = "Drug resistance, HER-2, Herceptin, NF-κB, Radiotherapy resistance, Review",
author = "Ahmed, {Kazi M.} and Ning Cao and Jian-Jian Li",
year = "2006",
month = "11",
language = "English (US)",
volume = "26",
pages = "4235--4243",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - HER-2 and NF-κB as the targets for therapy-resistant breast cancer

AU - Ahmed, Kazi M.

AU - Cao, Ning

AU - Li, Jian-Jian

PY - 2006/11

Y1 - 2006/11

N2 - HER-2 (also called ErbB2 or Neu) tyrosine kinase, one of the four members of ErbB receptor family (ErbB1, i.e., EGFR, ErbB2, ErbB3 and ErbB4), plays a critical role in the control of diverse cellular functions involved in differentiation, proliferation, migration and cell survival via multiple signal transduction pathways. Overexpression of HER-2, observed in HER-2-positive breast cancer patients, is believed to cause the tumor resistance to an array of anti-cancer agents and poor prognosis. Although HER-2 antibodies have shown growth inhibitory effects, more efficient molecular targets against HER-2-mediated tumor resistance need to be developed. The molecular mechanisms underlying HER-2-mediated tumor resistance, especially the connections between HER-2 and therapy-resistant signaling networks, need to be further investigated. NF-KB, a key stress transcription factor that can initiate a pro-survival network, was found to be activated in many cancer cells overexpressing HER-2 and to be responsible for the radiation resistance in HER-2 transfected breast cancer cells. Recent findings in literature and data from this laboratory suggest a possible co-operation between HER-2 and NF-κB in signaling tumor resistance to radiotherapy. This review will discuss the mechanisms of HER-2 mediated NF-κB signaling pathway and potential target for therapeutic intervention.

AB - HER-2 (also called ErbB2 or Neu) tyrosine kinase, one of the four members of ErbB receptor family (ErbB1, i.e., EGFR, ErbB2, ErbB3 and ErbB4), plays a critical role in the control of diverse cellular functions involved in differentiation, proliferation, migration and cell survival via multiple signal transduction pathways. Overexpression of HER-2, observed in HER-2-positive breast cancer patients, is believed to cause the tumor resistance to an array of anti-cancer agents and poor prognosis. Although HER-2 antibodies have shown growth inhibitory effects, more efficient molecular targets against HER-2-mediated tumor resistance need to be developed. The molecular mechanisms underlying HER-2-mediated tumor resistance, especially the connections between HER-2 and therapy-resistant signaling networks, need to be further investigated. NF-KB, a key stress transcription factor that can initiate a pro-survival network, was found to be activated in many cancer cells overexpressing HER-2 and to be responsible for the radiation resistance in HER-2 transfected breast cancer cells. Recent findings in literature and data from this laboratory suggest a possible co-operation between HER-2 and NF-κB in signaling tumor resistance to radiotherapy. This review will discuss the mechanisms of HER-2 mediated NF-κB signaling pathway and potential target for therapeutic intervention.

KW - Drug resistance

KW - HER-2

KW - Herceptin

KW - NF-κB

KW - Radiotherapy resistance

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=33846006906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846006906&partnerID=8YFLogxK

M3 - Article

VL - 26

SP - 4235

EP - 4243

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -